Search

In a retrospective study, a patient developed tardive dyskinesia and tardive dystonia while receiving antipsychotic treatment with amisulpride. The specific details about the patient's age, sex, dosage, and route of administration were not provided. The patient was subsequently treated with clozapine, but the outcome of this treatment was not stated. [Extracted from the article]

A case report published in Reactions Weekly describes the lack of efficacy of amisulpride and risperidone in treating schizoaffective disorder in an adult woman. The patient had a history of paranoid personality traits in her family and began experiencing psychotic symptoms in her adolescence. She was initially treated with haloperidol and later diagnosed with schizophrenia. After a decade of stability, she developed manic episodes and was prescribed amisulpride and clozapine. However, her symptoms persisted and she was admitted to a psychiatric unit. Electroconvulsive therapy and off-label treatment with drospirenone were eventually added to her medication regimen, resulting in partial improvement. [Extracted from the article]

A case report published in Reactions Weekly describes a 65-year-old woman with paranoid schizophrenia who exhibited a lack of efficacy with risperidone and developed sinus arrest during treatment with amisulpride. The woman initially received treatment with risperidone but it was stopped due to poor efficacy. She then started treatment with amisulpride and experienced sinus bradycardia and a decrease in heart rate. After discontinuing amisulpride and switching to olanzapine, her heart rate returned to normal. This case highlights the potential cardiac effects of amisulpride and the need for careful monitoring during treatment. [Extracted from the article]

A case series published in Reactions Weekly describes a 30-year-old man with schizophrenia who developed syndrome of inappropriate antidiuretic hormone secretion (SIADH) while being treated with amisulpride. The man was found unconscious and convulsing and experienced a tonic-clonic epileptic crisis before being hospitalized. He was diagnosed with SIADH based on symptoms and investigational findings, and it was determined that amisulpride was the cause. The man was treated with antibiotics for suspected sepsis but later stopped. Urine and blood samples confirmed the presence of amisulpride and its metabolites. [Extracted from the article]

A 25-year-old man with treatment-resistant auditory hallucinations, vision-touch synesthesia, and reflex hallucinations experienced a lack of efficacy while being treated with amisulpride. Despite taking amisulpride for six months at a dose of 300mg, there was no improvement in his condition. The man was also taking clozapine. After discontinuing amisulpride and increasing the dose of clozapine, the man experienced noticeable improvement. [Extracted from the article]

A 25-year-old man with treatment-resistant auditory hallucinations, vision-touch synesthesia, and reflex hallucinations experienced a lack of efficacy while being treated with amisulpride. Despite taking amisulpride for six months at a dose of 300mg, there was no improvement in his condition. The man was also taking clozapine. After discontinuing amisulpride and increasing the dose of clozapine, the man experienced noticeable improvement. [Extracted from the article]

However, despite clozapine therapy, he had persistence of positive symptoms according to the positive and negative syndrome scale and was diagnosed with clozapine-resistant schizophrenia (lack of efficacy). However, despite clozapine therapy, he had persistence of positive symptoms according to the positive and negative syndrome scale and was diagnosed with clozapine-resistant schizophrenia (lack of efficacy). However, despite clozapine therapy, she had persistence of positive symptoms according to the positive and negative syndrome scale and was diagnosed with clozapine-resistant schizophrenia (lack of efficacy). [Extracted from the article]

A 59-year-old woman with Lewy body dementia (LBD) experienced various toxicities while being treated with antipsychotic medications. She initially received risperidone, but had severe motor side effects. She then tried clozapine, but developed acute myocarditis and intolerance to the medication. Quetiapine and amisulpride were also ineffective and caused somnolence and parkinsonism, respectively. Finally, she was prescribed off-label pimavanserin, which improved her LBD symptoms. [Extracted from the article]

However, she developed tardive dyskinesia and pharmacological parkinsonism secondary to amisulpride, which had been stable for 15 years. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An 83-year-old woman developed pharmacological parkinsonism, tardive dyskinesia and belly dance dyskinesia (BDD) during treatment with amisulpride for bipolar syndrome. [Extracted from the article]

Based on history and mental examination, he was diagnosed with autism spectrum disorder [ASD; I outcome not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 33-month-old boy developed autism spectrum disorder following I in-utero i exposure and exposure during breasfeeding to amisulpride and haloperidol. [Extracted from the article]

One month after initiation of treatment, his ISB resolved and he had no extrapyramidal signs. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An 86-year-old man exhibited lack of efficacy following treatment with amisulpride and risperidone for inappropriate sexual behaviour [ISB; I routes not stated i ]. The man developed memory impairment, disorientation and ISB after a head injury with traumatic subarachnoid haemorrhage and occipital bone fracture in 2012. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn retrospective study of 50 patients, et al. patient [age and sex not stated] was described, who developed QTc prolongation during antipsychotic therapy with clozapine [route, dosage, duration of treatment to reaction onset and outcome not stated]. The patient received antipsychotic therapy with clozapine. However, the patient was found to developed new QTc prolongation related to clozapine. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn retrospective study of 50 patients, et al. patient [age and sex not stated] was described, who developed QTc prolongation during antipsychotic therapy with clozapine [route, dosage, duration of treatment to reaction onset and outcome not stated]. The patient received antipsychotic therapy with clozapine. However, the patient was found to developed new QTc prolongation related to clozapine. [Extracted from the article]

A 36-year-old woman with schizophrenia developed tardive dystonia while being treated with olanzapine, amisulpride, quetiapine, and clozapine. She did not respond to treatment with trihexyphenidyl, tetrabenazine, and clonazepam for the dystonia. Her symptoms included abnormal movements, back pain, and stiffness in her back and abdominal muscles. After stopping the previous medications, her treatment with clozapine was optimized and she received zolpidem, which improved her symptoms of tardive dystonia. [Extracted from the article]

A patient with schizophrenia experienced lack of efficacy while being treated with amisulpride, aripiprazole, clozapine, sertraline, and trazodone. They also developed rhabdomyolysis while taking cariprazine. Despite trying different medications, the patient did not see improvement in their symptoms. Electroconvulsive therapy was eventually used, which initially led to improvement but later the symptoms returned. The patient's medication was adjusted, but there was still no improvement. Rhabdomyolysis was attributed to cariprazine and the medication was stopped, resulting in remission of the symptoms. [Extracted from the article]

A retrospective study involving 19 patients was conducted to examine the reactions and lack of efficacy of multiple drugs in treating various conditions such as Niemann Pick type C disease, schizophrenia, and schizoaffective disorder. The study found that patients exhibited side effects, lack of efficacy, or treatment noncompliance with drugs such as alimemazine, amisulpride, aripiprazole, chlorpromazine, clozapine, and many others. Some patients were later diagnosed with Niemann Pick type C disease, which was associated with their psychiatric symptoms. The study highlights the need for further research and personalized treatment approaches for these conditions. [Extracted from the article]

This article discusses three cases of patients with schizophrenia who experienced various toxicities while being treated with clozapine, paliperidone, and pipotiazine. The first case involved a man in his 20s who developed constipation, weight gain, hypersalivation, and tachycardia while on clozapine treatment. The second case described a man in his early adulthood who experienced weight gain and metabolic changes while on paliperidone and clozapine treatment. The third case involved a man in his late 30s who exhibited lack of efficacy with pipotiazine and showed improvement when clozapine was added to his treatment. These cases highlight the potential adverse effects and challenges in managing schizophrenia with antipsychotic medications. [Extracted from the article]

A 60-year-old man developed agranulocytosis, a condition characterized by a low white blood cell count, while being treated with amisulpride for schizophrenia. Prior to taking amisulpride, the man had been treated with other antipsychotic drugs and neuroleptics. Three days after starting amisulpride, he experienced agranulocytosis, but the condition resolved after discontinuing the medication. The agranulocytosis was determined to be a result of the amisulpride therapy. [Extracted from the article]

A 55-year-old man developed venous thromboembolism (VTE) and pulmonary embolism while being treated for paranoid schizophrenia with ziprasidone, amisulpride, and risperidone. He experienced sedation and weight gain as side effects of amisulpride and risperidone, leading to a switch in his medication to ziprasidone. However, he was later hospitalized with breathlessness and diagnosed with pulmonary embolism and VTE, which were considered to be caused by ziprasidone. Treatment with acenocoumarol and support stockings was planned. [Extracted from the article]

A 60-year-old man developed agranulocytosis, a condition characterized by a low white blood cell count, while being treated with amisulpride for schizophrenia. Prior to taking amisulpride, the man had been treated with other antipsychotic drugs and neuroleptics. Three days after starting amisulpride, he experienced agranulocytosis, but the condition resolved after discontinuing the medication. The agranulocytosis was determined to be a result of the amisulpride therapy. [Extracted from the article]

A 55-year-old man developed venous thromboembolism (VTE) and pulmonary embolism while being treated for paranoid schizophrenia with ziprasidone, amisulpride, and risperidone. He initially experienced sedation and weight gain from amisulpride and risperidone, so his treatment was switched to ziprasidone. However, he was later hospitalized with breathlessness and diagnosed with pulmonary embolism and VTE, which were considered to be secondary to ziprasidone. Treatment with acenocoumarol and support stockings was planned. [Extracted from the article]

Based on presenting symptoms and investigational findings, a diagnosis of amisulpride-induced gait disorder was made [ I duration of treatment to reaction onset not stated i ]. At the current presentation, his neurological examination revealed an unusual gait disorder characterised by rigidity, ataxia and limping with some instability but without falls. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 60-year-old man developed gait disorder during treatment with amisulpride for depressive disorder. [Extracted from the article]

In a study of 7 patients, 6 patients including 5 women and one man, aged 35-70 years were described, who developed increased appetite, weight gain, galactorrhoea, amenorrhoea, elevated prolactin levels (PRL), tenderness in breasts during treatment with amisulpride or withdrawal syndrome following withdrawal of amisulpride given as an off-label treatment for depression [ I routes not stated; not all outcomes stated i ]. On presentation, an off-label treatment with amisulpride 50mg was added to her treatment regimen as an augmentation therapy. As a result, an off-label treatment with amisulpride 50mg was added to his treatment regimen as an augmentation therapy, which resulted in the improvement of his mood, and he was discharged in good condition 2 weeks later. During one of these short depressive episodes, an off-label treatment with amisulpride 50mg was added to her treatment regimen as an augmentation therapy. [Extracted from the article]

His creatine kinase and creatine kinase levels isoenzymes returned to normal range. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 60-year-old man developed psychomotor seizures during treatment with amisulpride, and exhibited increased level of creatine kinase and creatine kinase isoenzymes during treatment with olanzapine for schizophrenia [ I routes and times to reactions onsets not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 56-year-old woman developed severe extra-pyramidal effects during treatment with amisulpride. Amisulpride [ I dosage, route and indication not stated i ] was started, but she developed severe extra-pyramidal effects [ I time to reaction onset and outcome not stated i ]. Three years following the ischaemic stroke, she developed delusional parasitosis, which improved following treatment with aripiprazole. [Extracted from the article]

A 27-year-old man with schizophrenia exhibited a lack of efficacy during treatment with multiple antipsychotic drugs, including risperidone, quetiapine, olanzapine, haloperidol, and amisulpride. Despite receiving these medications, his condition did not improve. He was then treated with clozapine and aripiprazole, which resulted in some improvement after six months. This case suggests that the patient's schizophrenia was refractory to the initial medications but responded to the subsequent treatment. [Extracted from the article]

A 27-year-old man with schizophrenia exhibited a lack of efficacy during treatment with multiple drugs, including risperidone, quetiapine, olanzapine, haloperidol, and amisulpride. He was hospitalized due to significant behavioral and cognitive disorganization. Despite receiving these medications, there was no improvement in his condition, suggesting that his schizophrenia was refractory to these drugs. He later received treatment with clozapine and aripiprazole, which resulted in improvement and allowed him to resume his studies. [Extracted from the article]

A retrospective review of 22 patients with treatment-refractory psychotic disorders found that off-label use of melperone showed lack of efficacy in treating schizophrenia, schizoaffective disorder depressive type, and severe depression with psychotic symptoms. The patients had previously been treated with various medications including clozapine, olanzapine, amisulpride, pipotiazine, risperidone, aripiprazole, haloperidol, zuclopenthixol, and chlorpromazine, but did not respond well to these treatments. Some patients experienced adverse effects such as hypertension, seizures, neutropenia, hypersalivation, constipation, pericarditis, myocarditis, sedation, and weight gain. Overall, melperone therapy also showed limited effectiveness, with some patients experiencing extrapyramidal side effects. [Extracted from the article]

Subsequently, she exhibited lack of efficacy during treatment with aripiprazole and quetiapine for schizophreniform disorder, and developed akathisia following tapering of amisulpride [ I routes not stated i ]. Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report. Amisulpride/aripiprazole/quetiapine: hyperprolactinaemia, akathisia following amisulpride tapering and lack of efficacy: case report. [Extracted from the article]

This article presents three case reports of men aged 20-27 who experienced various toxicities while being treated for schizophrenia or obsessive-compulsive symptoms. The first case involved a man who developed oculogyric crisis despite changing medications. The second case described a man who experienced blepharospasm that persisted despite a change in medication. The third case involved a man who developed loss of libido, sedation, and sialorrhoea while being treated with different medications. In each case, the symptoms were resolved when the patients switched to quetiapine as a monotherapy. [Extracted from the article]

A 22-year-old man experienced various toxicities while being treated for schizophrenia and hyperlipidemia. He developed tachycardia, mild constipation, and elevated troponin T levels during treatment with clozapine and rosuvastatin. The man also exhibited lack of efficacy with aripiprazole and paliperidone. His symptoms improved with the use of clozapine, but he still experienced elevated troponin T levels. The man's troponin T levels gradually decreased over time, and he showed functional improvement in his schizophrenia symptoms. Sertraline was added to his treatment for low mood and anxiety. [Extracted from the article]

A case report published in Reactions Weekly describes a 42-year-old man with schizophrenia who developed sinus tachycardia while being treated with clozapine. The patient's symptoms gradually responded to the medication, but he experienced persistent tachycardia. As a result, he was prescribed ivabradine for the tachycardia, but after 5 days of treatment, he developed delirium. The ivabradine was discontinued, and the delirium symptoms improved. The patient continued to be treated with clozapine and showed improvement in his schizophrenia. [Extracted from the article]

A 50-year-old man developed tardive dyskinesia while being treated with chlorpromazine and risperidone for delusional disorder. He initially showed improvement and was discharged on the same medications, but after 7 months, he began experiencing symptoms such as tongue protrusion, irregular jaw movements, and tremors. The tardive dyskinesia was attributed to the chlorpromazine and risperidone, and the man's medication was adjusted. After receiving off-label treatment with clonazepam and transitioning to quetiapine, the tardive dyskinesia went into remission. [Extracted from the article]

A retrospective chart review was conducted on 16 patients with schizophrenia who exhibited drug ineffectiveness while being treated with various antipsychotic medications. Two of these patients also developed hyperprolactinemia with galactorrhea or extrapyramidal symptoms while taking clozapine and lurasidone. The patients' treatment was switched to lurasidone and clozapine, resulting in improvement in their schizophrenia symptoms. However, two patients experienced side effects from lurasidone and discontinued the therapy without consulting their doctor. [Extracted from the article]

A 39-year-old man with treatment-resistant schizophrenia developed tardive seizures and agranulocytosis while being treated with clozapine, and an erythematous rash while being treated with lithium. His clozapine treatment was discontinued, but after failing modified electroconvulsive therapy, he reintroduced clozapine and gradually increased the dosage. However, he developed an erythematous rash after starting lithium, which was believed to be caused by the medication. The man was discharged from the hospital on clozapine and haloperidol with close follow-up. [Extracted from the article]

Drug overdose A 50-year-old man developed deep coma, respiratory insufficiency, bradycardia, generalised seizure, lactic acidosis, fixed dilated pupils, broad complex tachycardia, QT prolongation and hypotension secondary to drug intoxication following deliberate ingestion of amisulpride at an overdose in an attempt to commit suicide. Also, he exhibited a lack of efficacy during treatment with physostigmine for drug intoxication. A supraglottic airway device was inserted to keep the airways open, and the man was moved to the emergency department at a hospital in Germany, during which he had a generalised seizure, which stopped after treatment with midazolam. [Extracted from the article]

Additionally, she developed worsening of akathisia during treatment with amisulpride for tardive akathisia [ I routes not stated; not all dosages stated i ]. The Barnes akathisia rating scale score was 9, and the global clinical assessment of akathisia score was 5, which indicated severe akathisia. B Author comment: b I "We are reporting a case with late-onset paraphrenia (persistent delusional disorder) who manifested with [tardive akathisia] after 10 months of therapy with risperidone.". [Extracted from the article]

An adult woman [ I exact age at reaction onset not stated i ] developed hyperprolactinaemia and gained weight during treatment with amisulpride and paliperidone, respectively, for bipolar disorder [ I routes not stated i ]. Later, she developed several relapses due to treatment interruptions. In November 2018 (at 40 weeks + 4 days of gestation), she delivered a healthy girl via spontaneous vaginal delivery, with birth weight of 3500g and Apgar score of 9/10/10. [Extracted from the article]